{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:17:57Z","timestamp":1787242677106,"version":"build-2736575974"},"reference-count":52,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Asia"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jacasi.2026.03.034","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T19:24:01Z","timestamp":1780428241000},"page":"839-847","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["SGLT2 Inhibition as a Novel Therapeutic Strategy in Rheumatic Heart Disease"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7295-3041","authenticated-orcid":false,"given":"Olivier","family":"Morel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh Trung","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesl","family":"Z\u00fchlke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Jouven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7034-1466","authenticated-orcid":false,"given":"Benjamin","family":"Marchandot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0992-1805","authenticated-orcid":false,"given":"Gregg","family":"Pressman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceeya","family":"Patton-Bolman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Roffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Pibarot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jacasi.2026.03.034_bib1","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jacasi.2025.03.011","article-title":"Epidemiology of valvular heart disease in Asia Pacific Region","volume":"5","author":"So","year":"2025","journal-title":"JACC Asia"},{"key":"10.1016\/j.jacasi.2026.03.034_bib2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jacc.2022.09.050","article-title":"Rheumatic heart disease: JACC focus seminar 2\/4","volume":"81","author":"Dougherty","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.03.034_bib3","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jacbts.2024.02.012","article-title":"Human aortic stenotic valve-derived extracellular vesicles induce endothelial dysfunction and thrombogenicity through AT1R\/NADPH oxidases\/SGLT2 pro-oxidant pathway","volume":"9","author":"Hmadeh","year":"2024","journal-title":"JACC Basic Transl Sci"},{"issue":"6","key":"10.1016\/j.jacasi.2026.03.034_bib4","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.125.041701","article-title":"Detrimental effects of plasma from patients with severe aortic stenosis on valvular endothelial cells: role of proinflammatory cytokines and factor Xa","volume":"15","author":"Trimaille","year":"2026","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacasi.2026.03.034_bib5","first-page":"e41","article-title":"2025 Heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"151","author":"Martin","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2026.03.034_bib6","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/CIRCULATIONAHA.116.024769","article-title":"Clinical outcomes in 3,343 children and adults with rheumatic heart disease from 14 low- and middle-income countries: two-year follow-up of the Global Rheumatic Heart Disease Registry (the REMEDY Study)","volume":"134","author":"Zuhlke","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2026.03.034_bib7","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.jacasi.2025.03.010","article-title":"Characteristics and problems of rheumatic heart disease in Indonesia: the Ina-RHD Multicenter Study","volume":"5","author":"Soesanto","year":"2025","journal-title":"JACC Asia"},{"key":"10.1016\/j.jacasi.2026.03.034_bib8","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s12872-025-04756-y","article-title":"Heart failure outcomes in Sub-Saharan Africa: a scoping review of recent studies conducted after the 2022 AHA\/ACC\/HFSA guideline release","volume":"25","author":"Siddikatou","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jacasi.2026.03.034_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.101216","article-title":"Rwanda RHD Research Network: central hub for international collaborative efforts to tackle rheumatic heart disease","volume":"3","author":"Mukeshimana","year":"2024","journal-title":"JACC Adv"},{"key":"10.1016\/j.jacasi.2026.03.034_bib10","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa2102074","article-title":"Secondary antibiotic prophylaxis for latent rheumatic heart disease","volume":"386","author":"Beaton","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.03.034_bib11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jacasi.2022.03.009","article-title":"Clinical benefits of sodium-glucose cotransporter 2 inhibitors and the mechanisms underlying their cardiovascular effects","volume":"2","author":"Kubota","year":"2022","journal-title":"JACC Asia"},{"key":"10.1016\/j.jacasi.2026.03.034_bib12","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/dom.14854","article-title":"Incident heart failure, arrhythmias and cardiovascular outcomes with sodium-glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: insights from a global federated electronic medical record database","volume":"25","author":"Fawzy","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.jacasi.2026.03.034_bib13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/cvr\/cvae257","article-title":"SGLT2 expression in human vasculature and heart correlates with low-grade inflammation and causes eNOS-NO\/ROS imbalance","volume":"121","author":"Mroueh","year":"2025","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacasi.2026.03.034_bib14","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ejhf.3145","article-title":"Myocardial sodium-glucose cotransporter 2 expression and cardiac remodelling in patients with severe aortic stenosis: the BIO-AS study","volume":"26","author":"Scisciola","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacasi.2026.03.034_bib15","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jtha.2023.09.022","article-title":"COVID-19 promotes endothelial dysfunction and thrombogenicity: role of proinflammatory cytokines\/SGLT2 prooxidant pathway","volume":"22","author":"Mroueh","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacasi.2026.03.034_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-000783","article-title":"Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet","volume":"7","author":"Xu","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.jacasi.2026.03.034_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106730","article-title":"Potential anti-inflammatory effect of dapagliflozin in HCHF diet- induced fatty liver degeneration through inhibition of TNF-alpha, IL-1beta, and IL-18 in rat liver","volume":"86","author":"ElMahdy","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jacasi.2026.03.034_bib18","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1007\/s40618-023-02162-9","article-title":"The anti-inflammatory and immunological properties of SGLT-2 inhibitors","volume":"46","author":"Bendotti","year":"2023","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.jacasi.2026.03.034_bib19","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.humimm.2021.03.004","article-title":"Changes in T helper cell\u2013related factors in patients with type 2 diabetes mellitus after empagliflozin therapy","volume":"82","author":"Borzouei","year":"2021","journal-title":"Hum Immunol"},{"key":"10.1016\/j.jacasi.2026.03.034_bib20","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00125-016-4158-2","article-title":"The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE (\u2013\/\u2013) mice fed a Western diet","volume":"60","author":"Han","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacasi.2026.03.034_bib21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijcard.2022.07.048","article-title":"Empagliflozin inhibits macrophage inflammation through AMPK signaling pathway and plays an anti-atherosclerosis role","volume":"367","author":"Fu","year":"2022","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1016\/j.jacasi.2026.03.034_bib22","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.3390\/ijms26041670","article-title":"Anti-inflammatory effects of SGLT2 inhibitors: focus on macrophages","volume":"26","author":"Rykova","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacasi.2026.03.034_bib23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12933-021-01252-3","article-title":"Angiotensin II\u2013induced upregulation of SGLT1 and 2 contributes to human microparticle-stimulated endothelial senescence and dysfunction: protective effect of gliflozins","volume":"20","author":"Park","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacasi.2026.03.034_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-65410-9","article-title":"SGLT2 inhibitors attenuate endothelial to mesenchymal transition and cardiac fibroblast activation","volume":"14","author":"Schmidt","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacasi.2026.03.034_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-16763-6","article-title":"Empagliflozin mitigates endothelial inflammation and attenuates endoplasmic reticulum stress signaling caused by sustained glycocalyx disruption","volume":"12","author":"Campeau","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacasi.2026.03.034_bib26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s00109-025-02615-z","article-title":"Dapagliflozin inhibits TGF-beta\u2013induced transdifferentiation of valvular interstitial cells and mitral valvular degeneration","volume":"104","author":"Sato","year":"2025","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.jacasi.2026.03.034_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103183","article-title":"Sodium-glucose cotransporter 2 inhibitors attenuate vascular calcification by suppressing endoplasmic reticulum protein thioredoxin domain containing 5 dependent osteogenic reprogramming","volume":"73","author":"Wu","year":"2024","journal-title":"Redox Biol"},{"key":"10.1016\/j.jacasi.2026.03.034_bib28","doi-asserted-by":"crossref","first-page":"7642","DOI":"10.1111\/jcmm.16601","article-title":"Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKalpha\/TGF-beta\/Smad signalling in type 2 diabetic rats","volume":"25","author":"Tian","year":"2021","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.jacasi.2026.03.034_bib29","first-page":"429","article-title":"Inhibition of miR-155-5p attenuates the valvular damage induced by rheumatic heart disease","volume":"45","author":"Chen","year":"2020","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.jacasi.2026.03.034_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115505","article-title":"Ertugliflozin ameliorates experimentally-induced colitis in rats by regulating the interplay between M1\/M2 macrophage polarization, tight junction proteins, and MicroRNA 155 expression","volume":"165","author":"Fouad","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jacasi.2026.03.034_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.177147","article-title":"Empagliflozin prevents TNF-alpha induced endothelial dysfunction under flow \u2014 the potential involvement of calcium and sodium-hydrogen exchanger","volume":"986","author":"Li","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jacasi.2026.03.034_bib32","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019274","article-title":"Dapagliflozin improves cardiac hemodynamics and mitigates arrhythmogenesis in mitral regurgitation-induced myocardial dysfunction","volume":"10","author":"Lin","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.jacasi.2026.03.034_bib33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12933-025-03024-9","article-title":"Comparative effects of second-line oral antidiabetic medications on atrial fibrillation risk in patients with type 2 diabetes: a nationwide retrospective cohort study","volume":"25","author":"Heo","year":"2026","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacasi.2026.03.034_bib34","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/ehf2.14169","article-title":"Dapagliflozin reduces pulmonary vascular damage and susceptibility to atrial fibrillation in right heart disease","volume":"10","author":"Dai","year":"2023","journal-title":"ESC Heart Fail"},{"issue":"18","key":"10.1016\/j.jacasi.2026.03.034_bib35","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.3390\/jcm12185898","article-title":"Effect of dapagliflozin on patients with rheumatic heart disease mitral stenosis","volume":"12","author":"Asrial","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacasi.2026.03.034_bib36","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12933-025-02748-y","article-title":"Diabetes mellitus aggravates myocardial inflammation and oxidative stress in aortic stenosis: a mechanistic link to HFpEF features","volume":"24","author":"Herwig","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacasi.2026.03.034_bib37","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jcmg.2020.07.042","article-title":"Empagliflozin ameliorates diastolic dysfunction and left ventricular fibrosis\/stiffness in nondiabetic heart failure: a multimodality study","volume":"14","author":"Santos-Gallego","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacasi.2026.03.034_bib38","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.03.034_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-085196","article-title":"Sodium-glucose cotransporter-2 inhibitors and risk of autoimmune rheumatic diseases: population based cohort study","volume":"391","author":"Hong","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.jacasi.2026.03.034_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2025.100336","article-title":"Epigenetic advances in rheumatic heart disease","volume":"11","author":"Zhu","year":"2025","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.jacasi.2026.03.034_bib41","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jcin.2024.11.036","article-title":"Effect of sodium-glucose cotransporter-2 inhibitors on the progression of aortic stenosis","volume":"18","author":"Shah","year":"2025","journal-title":"JACC Cardiovasc Interv"},{"issue":"2","key":"10.1016\/j.jacasi.2026.03.034_bib42","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3390\/jcm15020714","article-title":"Assessing potential valve-preserving effects of SGLT2 inhibitors in degenerative aortic stenosis: a propensity-matched study","volume":"15","author":"Morel","year":"2026","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacasi.2026.03.034_bib43","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s12933-024-02504-8","article-title":"SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI)","volume":"23","author":"Paolisso","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacasi.2026.03.034_bib44","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa2500366","article-title":"Dapagliflozin in patients undergoing transcatheter aortic-valve implantation","volume":"392","author":"Raposeiras-Roubin","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.03.034_bib45","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12933-025-02773-x","article-title":"Impact of SGLT2-inhibitors on acute kidney injury in diabetic patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI)","volume":"24","author":"Paolisso","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacasi.2026.03.034_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2025.102462","article-title":"Sodium glucose co-transporter 2 inhibitors in patients with heart failure and transcatheter aortic valve replacement","volume":"5","author":"Yasmin","year":"2026","journal-title":"JACC Adv"},{"issue":"25","key":"10.1016\/j.jacasi.2026.03.034_bib47","article-title":"Impact of SGLT2 inhibitors on long-term outcomes in TAVI patients with heart failure: a propensity-matched analysis","volume":"S1885-5857","author":"Obeidat","year":"2025","journal-title":"Rev Esp Cardiol (Eng Ed)"},{"issue":"19","key":"10.1016\/j.jacasi.2026.03.034_bib48","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.3390\/jcm14197001","article-title":"Association of SGLT2 inhibitors with mortality and bioprosthesis valve failure after TAVR: a propensity-matched cohort study","volume":"14","author":"Morel","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacasi.2026.03.034_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2025.101750","article-title":"The association between sodium-glucose cotransporter 2 inhibitors and bioprosthetic aortic valve degeneration","volume":"4","author":"Abbas","year":"2025","journal-title":"JACC Adv"},{"key":"10.1016\/j.jacasi.2026.03.034_bib50","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1002\/ehf2.15296","article-title":"Dapagliflozin effect on functional mitral regurgitation and myocardial remodelling: the DEFORM trial","volume":"12","author":"Huang","year":"2025","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacasi.2026.03.034_bib51","doi-asserted-by":"crossref","DOI":"10.1177\/17534666251351443","article-title":"Effects of sodium-glucose cotransport-2 inhibitors treatment in patients with pulmonary hypertension","volume":"19","author":"Obeidat","year":"2025","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jacasi.2026.03.034_bib52","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacasi.2022.05.005","article-title":"Stroke prevention in atrial fibrillation: a scientific statement of JACC: Asia (part 1)","volume":"2","author":"Chiang","year":"2022","journal-title":"JACC Asia"}],"container-title":["JACC: Asia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772374726002450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772374726002450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T03:33:45Z","timestamp":1780976025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772374726002450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2772374726002450"],"URL":"https:\/\/doi.org\/10.1016\/j.jacasi.2026.03.034","relation":{},"ISSN":["2772-3747"],"issn-type":[{"value":"2772-3747","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2 Inhibition as a Novel Therapeutic Strategy in Rheumatic Heart Disease","name":"articletitle","label":"Article Title"},{"value":"JACC: Asia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacasi.2026.03.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}